Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: Results of a randomized controlled trial

Antonio Palumbo, Sara Bringhen, Maria Teresa Petrucci, Pellegrino Musto, Fausto Rossini, Martina Nunzi, Vito Michele Lauta, Cesare Bergonzi, Anna Barbui, Tommaso Caravita, Antonio Capaldi, Patrizia Pregno, Tommasina Guglielmelli, Mariella Grasso, Vincenzo Callea, Alessandra Bertola, Federica Cavallo, Patrizia Falco, Cecilia Rus, Massimo MassaiaFranco Mandelli, Angelo Michele Carella, Enrico Pogliani, Anna Marina Liberati, Franco Dammacco, Giovannino Ciccone, Mario Boccadoro

Research output: Contribution to journalArticlepeer-review


High-dose therapy is an effective standard treatment for multiple myeloma patients. Evidence that intermediate-dose therapy improves survival is limited. At diagnosis, about 70% of patients are older than 65. Intermediate-dose regimen is very well tolerated in older patients. In a multicenter study, 194 patients were randomized to receive at diagnosis either conventional chemotherapy (6 courses of oral melphalan and prednisone [MP]) or intermediate-dose therapy (2 courses of melphalan at 100 mg/m2 [MEL100]) with stem cell support. Response rate was higher after MEL100. Near-complete remission (nCR) was 6% after MP and 25% after MEL100 (P = .0002). At 3 years, MEL100 increased event-free survival (EFS) from 16% to 37% and overall survival (OS) from 62% to 77% (P <.001). Similar results were observed in patients aged 65 to 70: nCR was 8% after MP and 25% after MEL100 (P = .05); at 3 years, MEL100 improved EFS from 18% to 31% (P = .01) and OS from 58% to 73% (P = .01). Patients aged 65 to 70 had a median OS of 37.2 months (MP) versus 58 months (MEL100). Intermediate-dose melphalan improves response rate, EFS, and OS in myeloma patients, specifically in those aged 65 to 70. It constitutes a more effective first-line regimen than standard treatment for elderly patients.

Original languageEnglish
Pages (from-to)3052-3057
Number of pages6
Issue number10
Publication statusPublished - Nov 15 2004

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: Results of a randomized controlled trial'. Together they form a unique fingerprint.

Cite this